Emergent salvage surgery for massive hemoptysis after proton beam therapy for lung cancer: a case report.

Broncho-pulmonary artery fistula Massive hemoptysis Proton beam therapy Salvage surgery

Journal

Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125

Informations de publication

Date de publication:
20 Apr 2021
Historique:
received: 15 02 2021
accepted: 07 04 2021
entrez: 20 4 2021
pubmed: 21 4 2021
medline: 21 4 2021
Statut: epublish

Résumé

Salvage surgery is an effective therapeutic option for patients experiencing relapses after chemoradiotherapy for advanced-stage lung cancer or after high-dose radiotherapy for early-stage lung cancer. We report a case involving an emergent salvage surgery for a patient with massive hemoptysis who developed lung cancer recurrence after undergoing proton beam therapy 7 years prior to presentation. A 70-year-old male patient was emergently admitted due to massive hemoptysis. He had undergone proton beam therapy for a stage I adenocarcinoma of the left upper lobe 7 years ago, and was receiving chemotherapy for local recurrence. We performed an emergent salvage pulmonary resection to achieve hemostasis. During the operation, we confirmed the presence of a left broncho-pulmonary arterial fistula, which was considered as the origin of the massive hemoptysis. We repaired the fistula between the pulmonary artery and left upper bronchus without incident; an orifice of the fistula at the left pulmonary artery was sutured using a non-absorbable monofilament, and the central portion of the orifice of the fistula at the left upper bronchus was closed with a mechanical stapling device. The postoperative diagnosis was of an adenocarcinoma-ypT3(pm1) N0M1a (dissemination)-IVA, ef1b. The patient has survived for over a year with the cancer in almost complete remission following the administration of an epidermal growth factor receptor tyrosine kinase inhibitor. Emergent salvage surgery demands high skill levels with optimal timing and correct patient selection. Our case suggested that the procedure played an important role in controlling serious bleeding and/or infectious conditions. Consequently, he could receive chemotherapy again and survive for over a year.

Sections du résumé

BACKGROUND BACKGROUND
Salvage surgery is an effective therapeutic option for patients experiencing relapses after chemoradiotherapy for advanced-stage lung cancer or after high-dose radiotherapy for early-stage lung cancer. We report a case involving an emergent salvage surgery for a patient with massive hemoptysis who developed lung cancer recurrence after undergoing proton beam therapy 7 years prior to presentation.
CASE PRESENTATION METHODS
A 70-year-old male patient was emergently admitted due to massive hemoptysis. He had undergone proton beam therapy for a stage I adenocarcinoma of the left upper lobe 7 years ago, and was receiving chemotherapy for local recurrence. We performed an emergent salvage pulmonary resection to achieve hemostasis. During the operation, we confirmed the presence of a left broncho-pulmonary arterial fistula, which was considered as the origin of the massive hemoptysis. We repaired the fistula between the pulmonary artery and left upper bronchus without incident; an orifice of the fistula at the left pulmonary artery was sutured using a non-absorbable monofilament, and the central portion of the orifice of the fistula at the left upper bronchus was closed with a mechanical stapling device. The postoperative diagnosis was of an adenocarcinoma-ypT3(pm1) N0M1a (dissemination)-IVA, ef1b. The patient has survived for over a year with the cancer in almost complete remission following the administration of an epidermal growth factor receptor tyrosine kinase inhibitor.
CONCLUSIONS CONCLUSIONS
Emergent salvage surgery demands high skill levels with optimal timing and correct patient selection. Our case suggested that the procedure played an important role in controlling serious bleeding and/or infectious conditions. Consequently, he could receive chemotherapy again and survive for over a year.

Identifiants

pubmed: 33877476
doi: 10.1186/s40792-021-01177-9
pii: 10.1186/s40792-021-01177-9
pmc: PMC8058119
doi:

Types de publication

Journal Article

Langues

eng

Pagination

98

Références

J Thorac Dis. 2017 Apr;9(Suppl 3):S193-S200
pubmed: 28446984
Ann Thorac Surg. 2020 Feb;109(2):e99-e101
pubmed: 31276644
Ann Thorac Surg. 2020 Oct;110(4):1123-1130
pubmed: 32473131
Ann Thorac Surg. 2019 Dec;108(6):1664-1670
pubmed: 31445048
J Cardiothorac Surg. 2018 Jan 22;13(1):13
pubmed: 29357877
J Surg Case Rep. 2015 Sep 04;2015(9):
pubmed: 26341785
Clin Lung Cancer. 2016 Sep;17(5):427-432
pubmed: 26725851
Lung Cancer. 2019 Jul;133:117-122
pubmed: 31200817
J Thorac Oncol. 2015 Nov;10(11):1616-24
pubmed: 26317918
Radiother Oncol. 2010 Apr;95(1):32-40
pubmed: 19733410
J Thorac Cardiovasc Surg. 2017 Aug;154(2):689-699
pubmed: 28495066
Lung Cancer. 2020 Jul;145:105-110
pubmed: 32422344
Jpn J Radiol. 2015 Jun;33(6):370-4
pubmed: 25900415

Auteurs

Haruaki Hino (H)

Department of Thoracic Surgery, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan. hinoh@hirakata.kmu.ac.jp.

Kahori Nakahama (K)

First Department of Internal Medicine, Division of Thoracic Oncology, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Makoto Ogata (M)

First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Kayoko Kibata (K)

First Department of Internal Medicine, Division of Thoracic Oncology, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Chika Miyasaka (C)

Department of Pathology and Laboratory Medicine, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Takahiro Utsumi (T)

Department of Thoracic Surgery, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Natsumi Maru (N)

Department of Thoracic Surgery, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Hiroshi Matsui (H)

Department of Thoracic Surgery, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Yohei Taniguchi (Y)

Department of Thoracic Surgery, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Tomohito Saito (T)

Department of Thoracic Surgery, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Koji Tsuta (K)

First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Tomohiro Murakawa (T)

Department of Thoracic Surgery, Kansai Medical University, 2-3-1 Shinmachi Hirakata-shi, Osaka, 573-1191, Japan.

Classifications MeSH